Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region
When developing new pharmaceutical products, it is very important to get to Phase I clinical trial in a fast, efficient and cost-effective way.
With Quick to Clinic™ for Oral Solid Dose, Thermo Fisher Scientific can deliver a drug in a phase-appropriate formulation for first-in-human studies in as little as 14 weeks from API receipt to release to clinic. This process includes one-month stability testing data to help complete regulatory submissions.
Watch this webcast to learn how to address early clinical development challenges, and how Thermo Fisher Scientific’s Quick to Clinic™ for Oral Solid Dose can help with: